

Breast Cancer Pathways: Neoadjuvant

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
Pathology: _____ Stage: _____
Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op ECOG Performance Status: _____ ICD-10 Code: _____
Biomarkers/Characteristics: (Select all that apply)
Estrogen Receptor (ER): __Negative __Positive OncotypeDx: __Low __Intermediate
Progesterone Receptor (PR): __Negative __Positive __High __Not Done/Reported
HER2 status by FISH/CISH: __Negative __Positive __Equivocal Menopausal Status: __Pre __Peri
or by IHC: __0 __1+ __2+ __3+ __Post __N/A (patient is male)

Neoadjuvant Therapy | HER2 Negative

___**ddAC** → **weekly T**: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel
___**TC**: docetaxel (Taxotere) and cyclophosphamide

Neoadjuvant Therapy | HER2 Positive

___**AC** → **TH**: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel and trastuzumab (Herceptin)*
___**TCH**: docetaxel (Taxotere), carboplatin, and trastuzumab (Herceptin)*

Neoadjuvant Therapy | HER2 Positive | Hormone Receptor (ER/PR) Negative

___**TCH+P**: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin)*, and pertuzumab (Perjeta)

*Administration of trastuzumab (Herceptin) is limited to 17 cycles (approximately 1 year)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.